| Literature DB >> 25888391 |
Upendra Thapa Shrestha1,2, Nabaraj Adhikari3, Rojina Maharjan4, Megha R Banjara5, Komal R Rijal6, Shital R Basnyat7, Vishwanath P Agrawal8.
Abstract
BACKGROUND: Cholera, an infectious disease caused by Vibrio cholerae, is a major public health problem and is a particularly burden in developing countries including Nepal. Although the recent worldwide outbreaks of cholera have been due to V. cholerae El Tor, the classical biotypes are still predominant in Nepal. Serogroup O1 of the V. cholerae classical biotype was the primary cause of a cholera outbreak in Kathmandu in 2012. Thus, this study was designed to know serotypes and biotypes of V. cholerae strains causing recent outbreak with reference to drug resistant patterns. Moreover, we also report the toxigenic strains of V. cholerae from both environmental and clinical specimens by detecting the ctx gene.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25888391 PMCID: PMC4350293 DOI: 10.1186/s12879-015-0844-9
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Serotyping and Biotyping of
|
|
|
|
|
|
|---|---|---|---|---|
| Serotyping | Agglutination (Mast Group and Denka Seiken Kit | Ogawa | 24 (100) | Serotypes Ogawa |
| Inaba | 0 | |||
| Hikojima | 0 | |||
| Biotyping | Voges Proskauer | 0 | Classical biotypes | |
| Polymyxin B sensitivity | 24 Sensitive (100) | |||
| Chicken cell agglutination | 0 |
General antibiotic susceptibility pattern of (total no = 24)
|
|
|
| ||
|---|---|---|---|---|
|
|
|
|
| |
| Ampicillin | 22 (100) | 0 | 2 (100) | 0 |
| Nalidixic acid | 22 (100) | 0 | 2 (100) | 0 |
| Ciprofloxacin | 2 (9.1) | 20 (90.9) | 0 | 2 (100) |
| Cotrimoxazole | 22 (100) | 0 (81.8) | 2 (100) | 0 |
| Cefotaxime | 4 (18.2) | 18 | 0 | 2 (100) |
| Chloramphenicol | 2 (9.1) | 20 (90.9) | 1 (50) | 1 (50) |
| Tetracycline | 0 | 22 (100) | 0 | 2 (100) |
| Erythromcycin | 20 (90.9) | 2 (9.1) | 2 (100) | 0 |
Antibiotic resistant profile of isolates
|
|
|
|
|---|---|---|
|
| ||
| CR1 | Ampicillin, Nalidixic acid, Cotrimoxazole | 2 (9.1) |
| CR2 | Ampicillin, Nalidixic acid, Cotrimoxazole, Erythromycin | 15 (68.2) |
| CR3 | Ampicillin, Nalidixic acid, Cotrimoxazole, Erythromycin, Cefotaxime | 3 (13.6) |
| CR4 | Ampicillin, Nalidixic acid, Cotrimoxazole, Erythromycin, Chloramphenicol, Ciprofloxacin | 1 (4.5) |
| CR5 | Ampicillin, Nalidixic acid, Cotrimoxazole, Erythromycin, Chloramphenicol, Ciprofloxacin, Cefotaxime | 1 (4.5) |
|
| ||
| ER1 | Ampicillin, Nalidixic acid, Cotrimoxazole, Erythromycin | 1 (50) |
| ER2 | Ampicillin, Nalidixic acid, Cotrimoxazole, Erythromycin, Chloramphenicol | 1 (50) |
Note: CR-Clinical resistant type, ER- Environmental resistant type.
Figure 1Amplification of gene in isolates (L-Ladder, PC-Positive control, NC-Negative control, clinical isolate; 210, 130, 262, 457 202, 274, 219, 306, 126, 256, 201, 248, 232, 297, 349, 222, 303, 335, 283, 117, 253 showing positive band).
Figure 2Amplification of gene in isolates (L-Ladder, PC-Positive control, NC-Negative control, clinical isolate; 130, 208 and environmental isolates; E9 E23 showing positive band).